Japan Compression Therapy Market Analysis

Japan Compression Therapy Market Executive Summary

Japan Compression Therapy Market was valued at $236 Mn in 2022 and is estimated to reach $379 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period.

Compression therapy, a medical procedure commonly used on limbs, aims to enhance blood circulation and reduce swelling. It is frequently employed for conditions like lymphedema, venous disorders, and specific edemas, with the primary goal of improving venous blood flow and preventing fluid buildup in tissues. Depending on the severity and individual needs, compression therapy may take various forms, such as elastic stockings, sleeves, or bandages. Techniques like compression wraps involve applying multiple layers for graduated compression, while intermittent pneumatic compression (IPC) mimics natural muscle contractions to aid venous return. Consulting with a healthcare provider is crucial to determine the most suitable technique and compression level, especially when developing comprehensive treatment plans for issues like poor circulation, swelling, or fluid retention.

In Japan, chronic venous disease (CVD) exhibits varying prevalence rates across different stages: 4.8% for the C1 stage (visible varicose veins), 0.7% for the C2 stage (leg swelling), 0.3% for the C3 stage (skin changes), and 0.1% for C4 stage (ulcers). Deep vein thrombosis (DVT) presents a prevalence of 0.85% among hospitalized patients and 10.3% among individuals undergoing venous ultrasonography screening. The incidence of Pulmonary Embolism (PE) in Japan is approximately 7.3 per 100,000 people. Noteworthy risk factors contributing to these venous disorders include the country's rapidly aging population, lifestyle factors such as prolonged periods of sitting or standing, obesity, and insufficient physical activity. Additionally, genetic predisposition plays a role, with certain genetic factors increasing susceptibility to venous disorders.

In compression therapy, smart garments use built-in sensors to track vital signs like temperature and pressure, giving users individualized feedback and treatment progress updates. Additionally, bio-responsive materials are incorporated into these clothes to improve comfort and effectiveness by automatically adjusting compression levels based on physiological data or user activity. Furthermore, to facilitate data analysis and remote monitoring, smart clothes are made to interface with telehealth platforms and smartphone apps. This integration makes it easier to manage patient care and increases patient engagement by facilitating the smooth exchange of important health information.

Market Dynamics

Market Growth Drivers

Advancements in Technology and Product Innovation: The growth of Japan's compression therapy market is driven by technological advancements and product innovations, such as smart compression garments with integrated sensors and connectivity, along with new materials and designs providing breathable and targeted options. The emphasis on personalization and customization further enhances treatment outcomes by tailoring products to individual physiology and conditions. This evolution in technology and product diversity meets the rising demands of consumers, propelling market expansion.

Rising Prevalence of Venous Disorders: The Japan Compression Therapy Market is experiencing growth driven by a notable increase in the incidence of deep vein thrombosis (DVT) and the potential surge in chronic venous disease (CVD). Lifestyle factors like obesity and decreased physical activity are contributing to a heightened risk of these conditions. As more individuals seek treatment for these vascular issues, the market for compression therapy in Japan is expanding, making it a significant driver of market growth.

Rising Geriatric Population: More than 36 Mn individuals in Japan, constituting 29% of the total population, are currently 65 years old or above. This percentage is expected to increase, reaching 40% by the year 2060. The rising need for compression therapy in Japan is mainly driven by the aging population. Japan is struggling with the difficulties arising from a rapidly growing elderly demographic, resulting in a heightened occurrence of conditions like lymphedema, varicose veins, and cardiovascular diseases.

Market Restraints

Lack of Insurance Coverage: Comprehensive insurance options for compression therapy are not widely accessible, thereby restricting patients' ability to receive treatment, particularly for preventive or extended durations.

High Cost of Products: Expensive compression garments, particularly from international brands, can be costly. For a significant segment of the populace, especially those with limited disposable income or those who depend on public healthcare programs, this could be an obstacle to access.

Low Patient Compliance: Consistently wearing compression apparel throughout the day may cause discomfort and restrictions, diminishing adherence and effectiveness of the treatment. This is particularly evident in non-medical scenarios such as sports recovery or daily wear. Insufficient patient education and awareness regarding the lasting advantages of compression therapy also play a role in fostering low compliance.

Healthcare Policies and Regulatory Landscape

In Japan, the regulation of therapeutic drugs is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA), which assesses the safety, effectiveness, and quality of pharmaceuticals, including treatment drugs, before their approval for market release. The Ministry of Health, Labor, and Welfare (MHLW) collaborates with the PMDA and holds a key role in formulating healthcare policies, ensuring that drugs comply with national health standards. Conditional approvals may be granted based on early-stage findings, with companies obligated to conduct post-marketing assessments to gather additional information on drug safety and effectiveness. The MHLW is responsible for managing the national health insurance system and influencing the coverage and reimbursement policies for treatment drugs. Japanese pharmaceutical firms frequently engage in global partnerships and licensing agreements to facilitate international cooperation in drug development and distribution.

Competitive Landscape

Key Players

• Mölnlycke Health Care AB
• Sigvaris
• GC Medical Supply Co.,
• Medi
• Bauerfeind
• Juzo
• McKesson Corporation
• Cardinal Health
• BSN Medical
• Hartmann Group